CONNECTA Therapeutics and Centre for Genomic Regulation to Present First-in-Class Program CTH120 for Fragile X Syndrome at FENS Forum 2026

/in

Preclinical data highlight restoration of cognitive, behavioral and synaptic deficits in Fragile X syndrome models Barcelona, Spain – 2 July 2026 – CONNECTA Therapeutics, a clinical-stage biotech company pioneering first-in-class neuroplasticity modulators to address unmet medical needs in central nervous system (CNS) disorders, today announced that it will present a poster, together with the Centre […]

Read more

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

/in

SERB assumes responsibility for the commercialization of Idefirix in transplantation in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA region The transaction significantly strengthens Hansa’s financial position and enables a robust US launch, subject to US approval of imlifidase Lund, Sweden, July 1, 2026. Hansa Biopharma AB (“Hansa” or “the Company”) (Nasdaq Stockholm: HNSA) and […]

Read more

R1 Therapeutics establishes world-class Scientific Advisory Board to support advancement of AP306 in Chronic Kidney Disease

/in

Seven internationally recognized nephrology experts join R1’s Scientific Advisory Board Strengthens scientific and clinical guidance as AP306 advances into global Phase 2b development for the treatment of hyperphosphatemia in chronic kidney disease Board chaired by Glenn M. Chertow, M.D., MPH, Professor of Medicine, Epidemiology and Population Health, and Health Policy at Stanford University School of […]

Read more

Poolbeg Pharma plc – POLB 001 patent granted in South Africa for the treatment or prevention of hypercytokinemia and severe influenza

/in

Patent decision strengthens Poolbeg’s intellectual property portfolio 30 June 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces it has received notification of the official decision to grant Poolbeg’s Immunomodulator II patent in South Africa, providing protection for POLB 001 for the prevention of hypercytokinaemia and […]

Read more

Hansa Biopharma announces ConfIdeS Phase 3 Abstract Selected for ‘What’s Hot, What’s New’ Plenary at ATC 2026

/in

Lund, Sweden, June 24, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that the ConfIdeS Phase 3 abstract titled “Superior 1-year eGFR Among Highly Sensitized Patients Desensitized with Imlifidase Compared to Control” has been selected to be highlighted at the closing plenary session “What’s Hot, What’s New” at the American Transplant Congress (ATC) 2026, […]

Read more
© Optimum Strategic Communications.